Crown Laboratories Inc., a provider of skincare solutions, and Revance Therapeutics Inc. have agreed to merge. Under the merger agreement, Crown will acquire all outstanding shares of Revance's common stock for $6.66 per share in cash, representing a total enterprise value of $924 million. Johnson City, Tennessee-based Crown was advised by Kirkland & Ellis and Lowenstein Sandler. The Kirkland team was led by partners Ed Lee and Marshall Shaffer. Revance, which is based in Nashville, Tennessee, was represented by a Skadden, Arps, Slate, Meagher & Flom team that included partners Howard Ellin and Demetrius Warrick.
Biotech & Pharmaceuticals
August 13, 2024, 9:37 AM